PRC
AGIO icon

Pearl River Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Pearl River Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,527
Closed -$389K – 409
2021
Q1 		$389K Sell
7,527
-1,677
-18% -$83.1K 0.12% 239
2020
Q4 		$399K Buy
9,204
+1,156
+14% +$45.7K 0.14% 220
2020
Q3 		$282K Buy
+8,048
New +$353K 0.12% 270
2020
Q2 		– Sell
-916
Closed -$32K – 274
2020
Q1 		$32K Buy
+916
New +$42.3K 0.06% 287

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pearl River Capital's AGIO Position: Q2 2021 in Review

Pearl River Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2021, closing a stake of 7,527 shares — an estimated $389K sold.

Pearl River Capital first reported a position in AGIO in Q1 2020 and held it in 4 quarters. The position peaked at $399K in Q4 2020. 185 funds tracked by Wall St. Rank hold AGIO as of Q2 2021.

  • Pearl River Capital reported no remaining Agios Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Pearl River Capital sold 7,527 Agios Pharmaceuticals shares in Q2 2021, an estimated $389K.
  • Pearl River Capital first reported a position in Agios Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Pearl River Capital's Agios Pharmaceuticals position peaked at $399K in Q4 2020.
  • 185 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2021.

Based on Pearl River Capital's 13F filing for Q2 2021, filed 13 Aug 2021.